DMSO, a sulfur-containing liquid that crosses skin, is applied to sore joints and injuries and instilled into the bladder for chronic bladder pain, its one approved use, where trials against a dummy treatment agree. Arthritis and tendon results are mixed, at best small; longevity ideas rest only on worm, mouse and cell studies. Garlic-like odor is near-universal. It reads as a targeted local tool, not an established longevity agent. (Full Review)

Protocol

Topical, standard practitioner protocol

50–70% solution or gel, 2–3× daily

Over the painful area, air-dried 20–30 min; up to 90% on thick skin, 50% or less on face, neck and thin skin

Bladder instillation (FDA-approved)

50 mL Rimso-50, retained 15 min

Every 2 weeks until relief, then less often; many urologists use six weekly instillations

CRPS protocol (Dutch academic centers)

50% cream, 5× daily

For complex regional pain syndrome, applied to the affected limb for 17 weeks or longer, alongside physiotherapy

Time to effect

Interstitial cystitis

4–12 weeks

Bladder benefits emerge over repeated instillations

Complex regional pain syndrome

About 2 months

Improvement in pain and impairment with 50% cream

Skin application

Within about an hour

Local effects on the treated area

Benefits

High: Relief of interstitial cystitis symptoms; healing and relapse prevention of duodenal ulcers; less dead tissue at mastectomy wound edges

Medium: Reduced pain and impairment in complex regional pain syndrome; relief of itchy protein-deposit skin patches; control and relapse prevention of ulcerative colitis; longer survival after gastric cancer surgery

Low: Musculoskeletal pain relief; tissue protection after chemotherapy leakage; lower brain pressure after head injury; healing of skin ulcers; improvement of systemic amyloidosis; vision in retinal degeneration

Speculative: Lifespan extension; brain protection and memory; anti-clotting and artery-wall protection; dampened chronic inflammation; cancer-cell maturation

Contraindications

Sulindac

Pregnancy or breastfeeding

Known DMSO hypersensitivity, or mast-cell disorders (systemic mastocytosis)

Urinary tract cancer (for bladder instillation)

Severe kidney impairment (eGFR below 30 mL/min/1.73 m²; for oral or intravenous use)

Heart block, significant arrhythmia or cardiac amyloidosis (for intravenous use)

Anticoagulants (for oral or intravenous DMSO)

Children

Key Interactions

Prescription drugs applied to the same skin (corticosteroids such as clobetasol, diclofenac, lidocaine, testosterone gel)

Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)

Beta-blockers (metoprolol) and digoxin, with intravenous DMSO

Sedatives and alcohol (zolpidem, diazepam, phenobarbital)

Over-the-counter skin products (methyl salicylate liniments, capsaicin, sunscreens, insect repellents)

Over-the-counter oral pain relievers (ibuprofen, naproxen)

Supplements with antiplatelet activity (fish oil, Ginkgo biloba, high-dose vitamin E, garlic extract)

Supplements with additive effects (MSM, N-acetylcysteine, curcumin)

Home-mixed preparations (iodine, essential oils, castor oil, herbal extracts)

Bladder instillation "cocktails" (heparin, triamcinolone, bupivacaine)

Risk & Side Effects

High: Garlic-like breath, taste and body odor; local irritation at the application site; heart-rhythm and neurological reactions with intravenous DMSO; headache, dizziness, drowsiness and nausea; allergic and histamine-type reactions

Low: Red-cell breakdown and fluid shifts with concentrated infusions; bleeding, including brain hemorrhage

Speculative: Eye lens changes; absorption of contaminants and co-applied chemicals; harm to a developing fetus; subtle cellular and gene-regulation changes

Monitoring

Marker	Target	Why
Hemoglobin (complete blood count)	Men 14–15.5 g/dL; women 13–14.5 g/dL	Detects hemolysis or bleeding
Haptoglobin and LDH	Haptoglobin 50–200 mg/dL; LDH 140–200 U/L	Confirms red-cell breakdown
ALT	Below 25 U/L	Screens liver stress
Creatinine and eGFR	eGFR above 90 mL/min/1.73 m²	Confirms kidney clearance of DMSO
Sodium and potassium	Sodium 139–142 mmol/L; potassium 4.0–4.8 mmol/L	Detects fluid and electrolyte shifts
Urinalysis (blood/hemoglobin)	Negative	Detects hemoglobin in urine from hemolysis
Slit-lamp eye examination	No lens clouding; stable eyeglass prescription	Screens for animal-reported lens changes
Symptom score (pain rating or bladder symptom index)	No established target; at least a 30% fall from own baseline	Defines treatment success
Electrocardiogram (for intravenous use)	Baseline reference point before intravenous use	Detects heart-rhythm changes with intravenous DMSO

Cadence: Baseline before repeated or systemic use; symptom scores at 2, 4 and 12 weeks; blood count, liver and kidney tests about every 6 months during repeated skin or bladder use; eye examination every 12 months during long-term use; blood count, electrolytes and urinalysis within 24 hours of each intravenous infusion

Qualitative Assessment

Pain intensity and stiffness during daily activities
Range of motion and walking or grip function
Urinary frequency, urgency and nighttime urination (for bladder use)
Sleep quality and daytime drowsiness
Skin condition at application sites
Tolerability of odor to the user and household

DMSO for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment